All drugs
All Europe delivery. Shipping time 7-10 days. Price for shipping individual for each country. Usually 40-50 euro. Payment when sending the goods.
Worldwide shipping possible too.
Kidney cancer
Jyseleca filgotinib) is a Janus kinase 1 (JAK1) inhibitor indicated for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).
Indications for the active ingredients of the drug Xospata
Relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations - as monotherapy.
Take at a dose of 120 mg 1 time per day.
Indications
Ulcerative colitis: treatment of exacerbations and prevention of relapses.
Crohn's disease: treatment of exacerbations.
Indications for the active substance SOTORASIB
As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy.
Showing
Chronic lymphocytic leukemia (CLL)
Gazyva® in combination with chlorambucil is indicated for the treatment of adult patients with chronic lymphocytic leukemia, who have not previously recovered from the treatment and may have a concomitant illness that makes it impossible to carry out therapy based on fludarabine at higher doses.
Follicular lymphoma (FL)
Gazyva® in combination with chemotherapy with further supportive therapy with the drug Gazyva®, in the available version, is indicated for the treatment of patients with previously untreated extended follicular lymphoma.
Gazyva® in combination with bendamustine followed by supportive therapy with Gazyva® is indicated for the treatment of patients with follicular lymphoma who do not respond to treatment rituximab or combination therapy, which included rituximab, or illness progressed within an hour or over a period of 6 months after treatment with rituximab or after combination therapy, which included rituximab.
Rheumatoid arthritis
RINVOK® indications for the treatment of rheumatoid arthritis of moderate to high stage of activity in adult patients, if adequate evidence has not been eliminated or there is an underlying intolerance to one or several anti-rheumatic drugs drugs that modify disease progression (DMARDs – disease-modifying antirheumatic drugs).
RINVOK® can be used as monotherapy or in combination with methotrexate.
Psoriatic arthritis
RINVOK® indications for the treatment of active psoriatic arthritis in adult patients in whom there is an inadequate response or intolerance to one or several anti-rheumatic drugs that modify the treatment sickness RINVOK® can be used as monotherapy or in combination with methotrexate.
Axial spondyloarthritis
Non-radiographic axial spondyloarthritis (nr-axial spondyloarthritis)
RINVOK® indications for the treatment of active non-radiographic axial spondyloarthritis in adults with objective signs of inflammation, confirmed by an elevated level of C-reactive protein (CRP) and/or MRI data, and with inadequate I qualify for therapy with non-steroidal anti-inflammatory drugs (NSAIDs).
Ankylosing spondylitis (AS, radiographic axial spondylitis)
RINVOK® indications for the treatment of active ankylosing spondylitis in adult patients with inadequate response to standard therapy.
Atopic dermatitis
RINVOK® is indicated for the treatment of moderate to severe atopic dermatitis in adults and children over 12 years of age, which are candidates for systemic therapy.
Virascovian colitis
RINVOK® indications for the treatment of viral colitis of mild or pronounced activity in adult patients with inadequate subtype, waste type or intolerance to standard therapy or biological drugs.
Crohn's disease
RINVOK® indications for the treatment of moderate to severe Crohn's disease in adult patients with inadequate response, loss of response or intolerance to standard therapy
or biological drugs.
Indication
Pomalidomide in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior course of treatment that included lenalidomide.
Pomalidomide in combination with dexamethasone is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have previously received at least two courses of treatment with lenalidomide and bortezomib and who have disease progression on the background of the last therapy.